<DOC>
	<DOCNO>NCT01957527</DOCNO>
	<brief_summary>Ticagrelor administration , whose molecule resemble adenosine , lead reduction overall mortality thrombotic cardiovascular ( CV ) event directly compare clopidogrel PLATO trial , implicate possible pleiotropic action drug . It show ticagrelor increase adenosine concentration , interfere red blood cell ' uptake inducing release ATP convert adenosine . Recent study healthy volunteer patient coronary artery disease ( CAD ) show ticagrelor increase coronary blood flow response intravenous adenosine administration . Ticagrelor administration , comparison P2Y12 inhibitor , may influence endothelial function , assess Peripheral Arterial Tonometry method ( EndoPAT 2000 system ( Itamar Medical , Caesarea , Israel ) , method evaluate endothelial dysfunction find positively correlate flow mediate dilatation ( FMD ) . This prospective , observational study , conduct patient coronary artery disease subject percutaneous coronary intervention ( PCI ) ticagrelor maintenance dose ( MD ) 90mg x 2 , stop treatment , due completion 1 year antiplatelet therapy . Eligible patient subject peripheral arterial tonometry Day 0 ( immediately receive last pill ticagrelor ) day 2 day 5 post study drug discontinuation . Peripheral blood sample take patient Day 0 genotype analysis .</brief_summary>
	<brief_title>Offset Ticagrelor 's Effect Endothelial Function Assessed With Peripheral Arterial Tonometry ( EndoPAT Assay )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age 1880 year old 2 . Patients Coronary Artery Disease receive ticagrelor maintenance dose ( MD ) 90mg x 2 discontinue treatment due completion 1 year dual antiplatelet therapy . 3 . Patients give write Informed Consent . 1 . Acute Coronary Syndrome 2 . Foreseeable need anticoagulant treatment within next 5 day 3 . Severe nonregulated theophylline/aminophylline administration chronic obstructive pulmonary disease 4 . Creatinine Clearance &lt; 30ml/min/1.73mm2 5 . HbA1c &gt; 10mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>endothelial function</keyword>
	<keyword>peripheral arterial tonometry</keyword>
</DOC>